|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Plummer M, Franceschi S and Muñoz N:
Epidemiology of gastric cancer. IARC Sci Publ. 157:311–326.
2004.
|
|
3
|
Catalano V, Labianca R, Beretta GD, Gatta
G, de Braud F and Van Cutsem E: Gastric cancer. Crit Rev Oncol
Hematol. 71:127–164. 2009. View Article : Google Scholar
|
|
4
|
Ozeben T: Mechanisms and strategies to
overcome multiple drug resistance in cancer. FEBS Lett.
580:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gillet JP and Gottesman MM: Mechanisms of
multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gillet JP, Efferth T and Remacle J:
Chemotherapy-induced resistance by ATP-binding cassette transporter
genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
|
|
7
|
Callaghan R, Crowley E, Potter S and Kerr
ID: P-glycoprotein: so many ways to turn it on. J Clin Pharmacol.
48:365–378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: the role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sarkaria JN, Kitange GJ, James CD, Plummer
R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to
alkylating agents in malignant glioma. Clin Cancer Res.
14:2900–2908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodriguez-Nieto S and Zhivotovsky B: Role
of alterations in the apoptotic machinery in sensitivity of cancer
cells to treatment. Curr Pharm Des. 12:4411–4425. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Viktorsson K, Lewensohn R and Zhivotovsky
B: Apoptotic pathways and therapy resistance in human malignancies.
Adv Cancer Res. 94:143–196. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim D, Dan HC, Park S, Yang L, Liu Q,
Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV and Cheng JQ:
AKT/PKB signaling mechanisms in cancer and chemoresistance. Front
Biosci. 10:975–987. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu P, ChenG H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI
|
|
16
|
Kunnimalaiyaan M, Ndiaye M and Chen H:
Apoptosis-mediated medullary thyroid cancer growth suppression by
the PI3K inhibitor LY294002. Surgery. 140:1009–1014. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu P, Xu B, Li J and Lu H: LY294002
inhibits leukemia cell invasion and migration through early growth
response gene 1 induction independent of phosphatidylinositol
3-kinase-Akt pathway. Biochem Biophys Res Commun. 377:187–190.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Imai Y, Yoshimori M, Fukuda K, Yamagishi H
and Ueda Y: The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated
drug resistance without affecting BCRP translocation. Oncol Rep.
27:1703–1709. 2012.PubMed/NCBI
|
|
19
|
Wu D, Tao J, Xu B, Qing W, Li P, Lu Q and
Zhang W: Phosphatidylinositol 3-kinase inhibitor LY294002
suppresses proliferation and sensitizes doxorubicin chemotherapy in
bladder cancer cells. Urol Int. 87:105–113. 2011. View Article : Google Scholar
|
|
20
|
Gelman AE, LaRosa DF, Zhang J, Walsh PT,
Choi Y, Sunyer JO and Turka LA: The adaptor molecule MyD88
activates PI-3 kinase signaling in CD4+ T cells and
enables CpG oligodeoxynucleotide-mediated costimulation. Immunity.
25:783–793. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Crowell JA, Steele VE and Fay JR:
Targeting the AKT protein kinase for cancer chemoprevention. Mol
Cancer Ther. 6:2139–2148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paweletz CP, Charboneau L, Bichsel VE,
Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin
EF III and Liotta LA: Reverse phase protein microarrays which
capture disease progression show activation of pro-survival
pathways at the cancer invasion front. Oncogene. 20:1981–1989.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
García MG, Alaniz LD, Cordo Russo RI,
Alvarez E and Hajos SE: PI3K/Akt inhibition modulates multidrug
resistance and activates NF-κB in murine lymphoma cell lines. Leuk
Res. 33:288–296. 2009.PubMed/NCBI
|
|
25
|
Filipits M: Mechanisms of cancer:
multidrug resistance. Drug Discov Today Dis Mech. 1:229–234. 2004.
View Article : Google Scholar
|
|
26
|
Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe
S, Mills GB and Unate H: Induction of human MDR1 gene expression by
2-acetylaminofluorene is mediated by effectors of the
phosphoinositide 3-kinase pathway that activate NF-κB signaling.
Oncogene. 21:1945–1954. 2002.PubMed/NCBI
|
|
27
|
Barancík M, Bohácová V, Sedlák J, Sulová Z
and Breier A: LY294,002, a specific inhibitor of PI3K/Akt kinase
pathway, antagonizes P-glycoprotein-mediated multidrug resistance.
Eur J Pharm Sci. 29:426–434. 2006.PubMed/NCBI
|
|
28
|
Gill PK, Gescher A and Gant TW: Regulation
of MDR1 promoter activity in human breast carcinoma cells by
protein kinase C isozymes α and θ. Eur J Biochem. 268:4151–4157.
2001.PubMed/NCBI
|
|
29
|
Vertegaal AC, Kuiperij HB, Yamaoka S,
Courtois G, van der Eb AJ and Zantema A: Protein kinase C-α is an
upstream activator of the IκB kinase complex in the TPA signal
transduction pathway to NF-κB in U2OS cells. Cell Signal.
12:759–768. 2000.
|
|
30
|
Chao X, Zao J, Xiao-Yi G, Li-Jun M and Tao
S: Blocking of PI3K/AKT induces apoptosis by its effect on NF-κB
activity in gastric carcinoma cell line SGC7901. Biomed
Pharmacother. 64:600–604. 2010.
|
|
31
|
Engelman JA: Targeting PI3K signalling in
cancer: opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nuutinen U, Postila V, Mättö M, Eeva J,
Ropponen A, Eray M, Riikonen P and Pelkonen J: Inhibition of
PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in
a human follicular lymphoma cell line. Exp Cell Res. 312:322–330.
2006.PubMed/NCBI
|
|
33
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Riedl SJ and Salvesen GS: The apoptosome:
signalling platform of cell death. Nat Rev Mol Cell Biol.
8:405–413. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Elumalai P, Gunadharini DN, Senthilkumar
K, Banudevi S, Arunkumar R, Benson CS, Sharmila G and Arunakaran J:
Induction of apoptosis in human breast cancer cells by nimbolide
through extrinsic and intrinsic pathway. Toxicol Lett. 215:131–142.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gillings AS, Balmanno K, Wiggins CM,
Johnson M and Cook SJ: Apoptosis and autophagy: BIM as a mediator
of tumour cell death in response to oncogene-targeted therapeutics.
FEBS J. 276:6050–6062. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tait SW and Green DR: Mitochondria and
cell death: outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kaufmann T, Strasser A and Jost PJ: Fas
death receptor signalling: roles of Bid and XIAP. Cell Death
Differ. 19:42–50. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al
Abdulmohsen S, Platanias LC, Al-Kuraya KS and Uddin S: Cross-talk
between NFκB and the PI3-kinase/AKT pathway can be targeted in
primary effusion lymphoma (PEL) cell lines for efficient apoptosis.
PLoS One. 7:e399452012.
|
|
41
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nicholson KM and Anderson NG: The protein
kinase B/Akt signalling pathway in human malignancy. Cell Signal.
14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shant J, Cheng K, Marasa BS, Wang JY and
Raufman JP: Akt-dependent NF-κB activation is required for bile
acids to rescue colon cancer cells from stress-induced apoptosis.
Exp Cell Res. 315:432–450. 2009.
|
|
44
|
Uchida M, Iwase M, Takaoka S, Yoshiba S,
Kondo G, Watanabe H, Ohashi M, Nagumo M and Shintani S: Enhanced
susceptibility to tumor necrosis factor-related apoptosis-inducing
ligand-mediated apoptosis in oral squamous cell carcinoma cells
treated with phosphatidylinositol 3-kinase inhibitors. Int J Oncol.
30:1163–1171. 2007.
|
|
45
|
Mantovani I, Cappellini A, Tazzari PL,
Papa V, Cocco L and Martelli AM: Caspase-dependent cleavage of
170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid
CEM cells. J Cell Physiol. 207:836–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
McDonald GT, Sullivan R, Paré GC and
Graham CH: Inhibition of phosphatidylinositol 3-kinase promotes
tumor cell resistance to chemotherapeutic agents via a mechanism
involving delay in cell cycle progression. Exp Cell Res.
316:3197–3206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shingu T, Yamada K, Hara N, Moritake K,
Osago H, Terashima M, Uemura T, Yamasaki T and Tsuchiya M: Growth
inhibition of human malignant glioma cells induced by the
PI3-K-specific inhibitor. J Neurosurg. 98:154–161. 2003. View Article : Google Scholar : PubMed/NCBI
|
